Your browser doesn't support javascript.
loading
SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion
Akatsuki Saito; Rigel Suzuki; Tadashi Maemura; Hesham Nasser; Keiya Uriu; Yusuke Kosugi; Kotaro Shirakawa; Kenji Sadamasu; Izumi Kimura; Jumpei Ito; Jiaqi Wu; Kiyoko Iwatsuki-Horimoto; Mutsumi Ito; Seiya Yamayoshi; Seiya Ozono; Erika P Butlertanaka; Yuri L Tanaka; Ryo Shimizu; Kenta Shimizu; Kumiko Yoshimatsu; Ryoko Kawabata; Takemasa Sakaguchi; Kenzo Tokunaga; Isao Yoshida; Hiroyuki Asakura; Mami Nagashima; Yasuhiro Kazuma; Ryosuke Nomura; Yasuhito Horisawa; Kazuhisa Yoshimura; Akifumi Takaori-Kondo; Masaki Imai; - The Genotype to Phenotype Japan (G2P-Japan) Consortium; So Nakagawa; Terumasa Ikeda; Takasuke Fukuhara; Yoshihiro Kawaoka; Kei Sato.
Affiliation
  • Akatsuki Saito; University of Miyazaki
  • Rigel Suzuki; Hokkaido University
  • Tadashi Maemura; University of Tokyo
  • Hesham Nasser; Kumamoto University
  • Keiya Uriu; The University of Tokyo
  • Yusuke Kosugi; The University of Tokyo
  • Kotaro Shirakawa; Kyoto University
  • Kenji Sadamasu; Tokyo Metropolitan Institute of Public Health
  • Izumi Kimura; The University of Tokyo
  • Jumpei Ito; The Institute of Medical Science, The University of Tokyo
  • Jiaqi Wu; Tokai University
  • Kiyoko Iwatsuki-Horimoto; Institute of Medical Science, University of Tokyo
  • Mutsumi Ito; Institute of Medical Science, University of Tokyo
  • Seiya Yamayoshi; University of Tokyo
  • Seiya Ozono; National Institute of Infectious Diseases
  • Erika P Butlertanaka; University of Miyazaki
  • Yuri L Tanaka; University of Miyazaki
  • Ryo Shimizu; Kumamoto University
  • Kenta Shimizu; Hokkaido University
  • Kumiko Yoshimatsu; Hokkaido University
  • Ryoko Kawabata; Hiroshima University
  • Takemasa Sakaguchi; Hiroshima University
  • Kenzo Tokunaga; National Institute of Infectious Diseases
  • Isao Yoshida; Tokyo Metropolitan Institute of Public Health
  • Hiroyuki Asakura; Tokyo Metropolitan Institute of Public Health
  • Mami Nagashima; Tokyo Metropolitan Institute of Public Health
  • Yasuhiro Kazuma; Kyoto University, Graduate School of Medicine
  • Ryosuke Nomura; Kyoto University
  • Yasuhito Horisawa; Kyoto University, Graduate School of Medicine
  • Kazuhisa Yoshimura; Tokyo Metropolitan Institute of Public Health
  • Akifumi Takaori-Kondo; Graduate School of Medicine, Kyoto University
  • Masaki Imai; Institute of Medical Science, University of Tokyo
  • - The Genotype to Phenotype Japan (G2P-Japan) Consortium; -
  • So Nakagawa; Tokai University
  • Terumasa Ikeda; Kumamoto University
  • Takasuke Fukuhara; Hokkaido University
  • Yoshihiro Kawaoka; University of Wisconsin-Madison
  • Kei Sato; Institute of Medical Science, The University of Tokyo
Preprint in English | bioRxiv | ID: ppbiorxiv-448820
ABSTRACT
During the current SARS-CoV-2 pandemic, a variety of mutations have been accumulated in the viral genome, and currently, four variants of concerns (VOCs) are considered as the hazardous SARS-CoV-2 variants to the human society1. The newly emerging VOC, the B.1.617.2/Delta variant, closely associates with a huge COVID-19 surge in India in Spring 20212. However, its virological property remains unclear. Here, we show that the B.1.617.2/Delta variant is highly fusogenic, and notably, more pathogenic than prototypic SARS-CoV-2 in infected hamsters. The P681R mutation in the spike protein, which is highly conserved in this lineage, facilitates the spike protein cleavage and enhances viral fusogenicity. Moreover, we demonstrate that the P681R-bearing virus exhibits higher pathogenicity than the parental virus. Our data suggest that the P681R mutation is a hallmark that characterizes the virological phenotype of the B.1.617.2/Delta variant and is closely associated with enhanced pathogenicity.
License
cc_by_nd
Full text: Available Collection: Preprints Database: bioRxiv Language: English Year: 2021 Document type: Preprint
Full text: Available Collection: Preprints Database: bioRxiv Language: English Year: 2021 Document type: Preprint
...